Skip to main content

CCTG at International Myeloma Society Meeting September 23-26

CCTG at International Myeloma Society Meeting September 23-26

It was great to see such a strong Canadian research presence at the International Myeloma Society (IMS) Annual Meeting, held September 23–26, 2026, in Glasgow, Scotland.

The CCTG MY13 study was highlighted from the podium during a session on optimal maintenance therapy. Presented by Dr. Pawlyn, the study was recognized for addressing important questions about current standards of care in multiple myeloma. The meeting also provided an opportunity to celebrate the achievements of Canadian researchers, with congratulations to Dr. Nizar Bahlis (University of Calgary), recipient of the 2026 International Myeloma Society Anderson Award. This well-deserved honour recognizes his contributions and international impact in multiple myeloma care and research.

CCTG research was further represented through two poster presentations: the TACtful trial and a MY13 trials-in-progress abstract. The full meeting concluded with Dr. Hira Miam, Co-Chair of CCTG’s Melanoma Working Group, presenting the final session highlighting the clinical advances and key findings from the 2026 annual meeting.

Together, these contributions highlight the strength and international reach of Canadian-led cancer research and the important role CCTG network investigators continue to play in advancing the field of multiple myeloma.

Dr. Annette Hay with the TACtful Trial poster
Dr. Hay TACtful Trial poster
Dr Nizar Bahlis recipient of the 2026 International Myeloma Society Anderson Award
Dr. Bahlis 2026 IMS Anderson Award
Dr. Florencia Comelles presents the MY13 trials in progress abstract poster
Dr. Comelles MY13 trials in progress
Dr. Hira Miam Clinical Highlights IMS 2026
Dr. Miam, Clinical Highlights IMS 2026 

 

 

 

 

 

 

 

 

Abstracts

CCTG IND.245 - A Phase II Study of Sonrotoclax plus Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Abstract: Development of BCMA-Specific TAC-T Cells: Enabling TACtful, a First-in-Human Study in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Poster Session PA-144

Authors: Laura Pearce, Joanne A. Hammill, Piriya Yoganathan, Marie-Pier Giard, Bonnie Bojovic, Christopher Baker, Ksenia Bezverbnaya, Janik Laframboise, Dominique Vaillant, Liana Medynski, Lorraine Haq, Ariel Perry, Laura Timms, Gabrielle Boudreau, Cynthia Thérien, Graeme Quest, Jennifer Quizi, Jean-Sébastien Delisle, Richard LeBlanc, Jonathan L. Bramson, Annette E. Hay

CCTG MY.13 - A Phase III Non-Inferiority Randomized Controlled Trial of Fixed Duration versus Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma   

Abstract: MY.13: A Canadian-Led Non-Inferiority Phase IIITrial in Progress Integrating Equity Principles in Transplant-Ineligible (TIE) Newly-Diagnosed (ND) Multiple Myeloma (MM): Poster Session PA-315

Authors: Maria F. Comelles, Hira Mian, Arleigh Robertson McCurdy, Rayan Kaedbey, Bethany Monteith, Danny Hill, Erma Gardner, Peter Anglin, Christopher P. Venner, Anthony J. Reiman, Nizar Abdel-Samad, Rami R. Kotb, Christie Kim, Julie Stakiw, Steven Shih, Martina Trinakus, Lauren Gerard, Ying Ling, Michael Sebag, Gail T. McDonald, Nolan M. Breault, Lois Shepherd, Bingshu E. Chen, Annette E. Hay